NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

COLON & RECTAL DISEASE ORIENTED WORKING GROUPS

<u>AGENDA</u>

OPEN SESSION

Venue: Stevenson Room, Delta Chelsea Hotel Date: Saturday, May 2nd, 2009 Time: 8:00 am

Chairs: CDOG: Dr. Derek Jonker & Dr. Sharlene Gill RDOG: Dr. Nancy Baxter & Dr. Te Vuong

7:15 am Continental Breakfast Available

8:00 am Welcome and Introduction / Membership Update

Dr. D. Jonker

8:15 am **Brief Update of active trials**

Dr. S. Gill

CRC.2 (N0147): A Randomized Phase III Trial of Oxaliplatin Plus 5-FU with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer

CRC.3 (E5202): A Randomized Phase III Study Comparing 5FU Leucovorin and Oxaliplatin versus 5FU Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

CRC.4 (ECOG 5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

CRC.5 (CALGB 80405): A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5FU / Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

CO.20: A Phase III Randomizes Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbitux[®]) versus Placebo in Combination with Cetuximab (Erbitux[®]) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma

CO.21: A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (CHALLENGE)

GASTROINTESTINAL DISEASE SITE AGENDA

SPRING 2009

IND.187: A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer

8:30 am INTERGROUP UPDATES

Colon Cancer Dr. D. Jonker/Dr. S. Gill

Rectal Cancer Dr. N. Baxter/Dr. T. Vuong

8:50 am UPDATE OF TRIALS IN DEVELOPMENT

9:05 am **OTHER**

9:15 am New Trial Proposals / Concepts for Development

9:45 am CLOSING REMARKS & ADJOURNMENT Dr. D. Jonker